Mammalian target of rapamycin (mTOR) is a protein kinase of the PI3K/Akt signaling
pathway. Activation of mTOR in response to growth, nutrient and energy signals leads to an …

The rapid development of new therapeutic agents that target specific molecular pathways
involved in tumour cell proliferation provides an unprecedented opportunity to achieve a …

BACKGROUND: A phase 3 trial demonstrated superiority at interim analysis for everolimus
over placebo in patients with metastatic renal cell carcinoma (mRCC) progressing on …

Mammalian target of rapamycin (mTOR) is a central controller of cell growth, proliferation,
metabolism and angiogenesis. mTOR signaling is often dysregulated in various human …

Everolimus is an oral antineoplastic agent that targets the raptor mammalian target of
rapamycin (mTORC1). The phosphatidylinositol 3‐kinase/mTOR signal transduction …

CONTEXT: The clinical management of patients with renal cell carcinoma (RCC) remains
difficult, and the development of new diagnostic, prognostic, and therapeutic tools is still …

Rationale: Noninfectious pneumonitis is a known class effect of mammalian target of
rapamycin (mTOR) inhibitors. Objectives: To assess the incidence, radiographic patterns …

Mammalian target of rapamycin (mTOR) is a key protein kinase controlling signal
transduction from various growth factors and upstream proteins to the level of mRNA …

A complex equilibrium of biological signals exists within the human body to regulate normal
cellular function and growth. Unfortunately, there are various ways in which disruption of …

Abstract The phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin
(mTOR) pathway mediates multiple cellular functions critical to tumor initiation, progression …